Detalhe da pesquisa
1.
Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia.
N Engl J Med
; 386(16): 1519-1531, 2022 04 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-35443108
2.
Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial.
Blood
; 141(2): 156-167, 2023 01 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35714312
3.
Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status.
Blood
; 139(14): 2145-2155, 2022 04 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34995344
4.
Flow cytometry-based measurable residual disease (MRD) analysis identifies AML patients who may benefit from allogeneic hematopoietic stem cell transplantation.
Ann Hematol
; 103(4): 1187-1196, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38291275
5.
Comparative Efficacy of Venetoclax-Based Combination Therapies and Other Therapies in Treatment-Naive Patients With Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy: A Network Meta-Analysis.
Value Health
; 26(12): 1689-1696, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37741447
6.
A 17-gene stemness score for rapid determination of risk in acute leukaemia.
Nature
; 540(7633): 433-437, 2016 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27926740
7.
Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.
Lancet Oncol
; 22(11): 1597-1608, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34672961
8.
3+7 Combined Chemotherapy for Acute Myeloid Leukemia: Is It Time to Say Goodbye?
Curr Oncol Rep
; 23(10): 120, 2021 08 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34350512
9.
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.
N Engl J Med
; 376(9): 836-847, 2017 03 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28249141
10.
Health-related quality of life in adults with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab.
Blood
; 131(26): 2906-2914, 2018 06 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-29739753
11.
Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia.
Nature
; 506(7488): 328-33, 2014 Feb 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-24522528
12.
Aplastic anaemia in pregnancy - a single centre, North American series.
Br J Haematol
; 184(3): 436-439, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30460693
13.
A phase II open-label study of aprepitant as anti-emetic prophylaxis in patients with acute myeloid leukemia (AML) undergoing induction chemotherapy.
Support Care Cancer
; 27(6): 2295-2300, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-30341536
14.
Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase III QUAZAR AML-001 trial.
Haematologica
; 108(10): 2820-2825, 2023 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36951156
15.
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.
Blood
; 126(3): 291-9, 2015 Jul 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-25987659
16.
Timely diagnosis and treatment of acute promyelocytic leukemia should be available to all.
Haematologica
; 107(3): 570-571, 2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34320788
17.
Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.
BMC Cancer
; 17(1): 852, 2017 Dec 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-29241450
18.
Predictive value of molecular remissions postconsolidation chemotherapy in patients with Core Binding Factor Acute Myeloid Leukemia (CBF-AML) - a single center analysis.
Hematol Oncol
; 35(4): 810-813, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27597292
19.
Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group.
Int J Mol Sci
; 18(2)2017 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28212292
20.
A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia.
Invest New Drugs
; 34(5): 614-24, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27406088